Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|8|4|395-403

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.8, Iss.4, 2007-05, pp. : 395-403

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future

By  

Current Medicinal Chemistry, Vol. 18, Iss. 7, 2011-03 ,pp. : 1038-1049

Bentham Science Publishers

Access to resources Recommend Favorite

Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 3, 2006-06 ,pp. : 199-207

Bentham Science Publishers

Access to resources Recommend Favorite

Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 wild–type JVM-2 But Not Towards p53 mutated BJAB Leukemic Cells

By  

Current Medicinal Chemistry, Vol. 20, Iss. 21, 2013-07 ,pp. : 2712-2722

Bentham Science Publishers

Access to resources Recommend Favorite

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment

By  

Mini Reviews in Medicinal Chemistry, Vol. 18, Iss. 2, 2018-01 ,pp. : 173-183

Bentham Science Publishers

Access to resources Recommend Favorite

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples

By di Iasio Maria  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1761-1765

Springer Publishing Company

Access to resources Recommend Favorite